ARQT News and Press, Arcutis Biotherapeutics Inc. From 08/20/23

2023-08-20 03:50:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights for an anti-inflammatory drug to ONE Bio in a $1 billion deal. Shanghai Sangon Biotech raised $290 million in funding from private investors. Hangzhou Zhongmei Huadong Pharma in-licensed China-SE ...

2023-08-18 16:41:38 ET More on Arcutis Biotherapeutics Arcutis: Zoryve - A Challenging Launch With Progress Arcutis Biotherapeutics: High OpEx And Crowded Markets Cloud Prospects Arcutis inks licensing deal to launch psoriasis cream in Asia Arcutis down 20% o...

WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis...

2023-08-10 09:14:59 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. ( ARQT ) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Arcutis: Zoryve - A Challenging Launch With Progress ...

Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...

2023-08-08 22:05:17 ET Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Eric McIntyre - Head-Investor Relations Frank Watanabe - President & Chief Executive Officer Ayisha Jeter - Interim-C...

2023-08-08 16:15:23 ET Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q2 GAAP EPS of -$1.16 beats by $0.08 . Revenue of $5.2M beats by $0.58M . Approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023. F...

Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of 2023, driven by nearly 40% demand growth as well as gross-to-net improvement Continued exp...

2023-08-02 13:00:00 ET Summary We've compiled a list of July investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured here are the investmen...

2023-07-28 05:31:08 ET Summary Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. The company has made progress with major pharmacy benefit managers and positioned Zoryve to be highly accessib...